Report
Valens Research

MD - Embedded Expectations Analysis - 2019 11 15

MEDNAX, Inc. (MD:USA) currently trades above recent averages relative to UAFRS-based (Uniform) Earnings, with a 26.6x Uniform P/E. However, even at these levels, the market has bearish expectations for the firm, and management may be concerned about their volume growth, contracts, and acquisitions

Specifically, management may lack confidence in their ability to sustain recent volume growth, and they may be concerned about the value of their recent maternal practice acquisitions. Furthermore, they may be exaggerating the strength of their support functions, and they may lack confidence in their ability to convert their anesthesia partners to their new comp model. Finally, they may be concerned about the strength of their book of contracts across their specialties.
Underlying
MEDNAX Inc.

MEDNAX provides physician services including newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology and other pediatric subspecialty care. The company's network comprised of physicians, including physicians who provide neonatal clinical care, primarily within hospital-based neonatal intensive care units, to babies born prematurely or with medical complications. The company also provides radiology services and teleradiology services. In addition to its national physician network, the company provides services to healthcare facilities and physicians, including the company's, through complementary businesses, consisting of a management services organization and a consulting services company.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch